Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Shilpa Biologicals commissions Antibody-Drug Conjugate (ADC) GMP manufacturing facility
Shilpa Biologicals, a material subsidiary of Shilpa Medicare, announced the commissioning of a state-of-the-art Antibody-Drug Conjugate (ADC) GMP manufacturing facility, purpose-built and designed to meet global regulatory approval standards including US FDA, EMA, and other major health authority requirements. The facility is fully operational, with GMP qualification protocols now actively underway, placing Shilpa on a clear path to commercial readiness.
Shilpa Medicare to acquire 30.4% stake in Spain's Gate2Brain with €7 million investment
The global glioblastoma treatment market is estimated at approximately $3 billion in 2025 and is projected to exceed $6 billion by 2035. The pediatric brain tumour market is estimated at around $1.5 billion, while the market for DIPG therapies is expected to reach nearly $1.2 billion by 2035.